A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control

International Journal of Rheumatic Diseases

Volumn 16, Issue 5, 2013, Pages 532-538

  Littlejohn, Geoffrey ^a   Roberts, Lynden ^b   Arnold, Mark ^c   Bird, Paul ^d   Burnet, Simon ^e   de Jager, Julien ^f   Griffiths, Hedley ^g   Nicholls, Dave ^h   Scott, James ⁱ   Zochling, Jane ^j   Tymms, Kathleen E ^k  

^a MONASH MEDICAL CENTRE   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c Arthritis Specialist Centre   (Australia)

^d Combined Rheumatology Practice ^*  (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f Olser House   (Australia)

^g Barwon Rheumatology Service   (Australia)

^h Coast Joint Care ^*  (Australia)

ⁱ Roche Products Pty Limited   (Australia)

^j UNIVERSITY OF TASMANIA   (Australia)

^k Canberra Rheumatology   (Australia)

more..

Author keywords

Biologic; Disease activity; Disease modifying anti rheumatic drugs; Remission; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; AUSTRALIA; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

BIOLOGIC; DISEASE ACTIVITY; DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS; REMISSION; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; BLOOD SEDIMENTATION; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84886548246     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12163     Document Type: Article

References (18)

1. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44, 2009-17.
2. de Punder YM, van Riel PL (2011) Rheumatoid arthritis: understanding joint damage and physical disability in RA. Nat Rev Rheumatol 7, 260-1.
3. Combe B, Landewe R, Lukas C et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66, 34-45.
4. Landewe RB, Boers M, Verhoeven AC et al. (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46, 347-56.
5. Grigor C, Capell H, Stirling A et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-9.
6. Korpela M, Laasonen L, Hannonen P et al. (2004) Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 50, 2072-81.
7. van Dongen H, van Aken J, Lard LR et al. (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56, 1424-32.
8. Smolen JS, Aletaha D, Bijlsma JW et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69, 631-7.
9. Curtis JR, Jain A, Askling J et al. (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40, 2-14 e11.
10. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44-8.
11. Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43, 1252-5.
12. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D (2010) Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 62, 857-64.
13. Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 56, 2135-42.
14. Montag K, Gingold M, Boers A, Littlejohn G (2011) Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J 41, 450-5.
15. Neubauer M, Schwartz J, Caracandas J et al. (2004) Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years. J Clin Oncol 22, 1872-7.
16. Makinen H, Kautiainen H, Hannonen P, Sokka T (2005) Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 64, 1410-3.
17. Aletaha D, Smolen JS (2011) Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 63, 3702-11.
18. Felson DT, Smolen JS, Wells G et al. (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70, 404-13.